antiarrythmic drugs

systematic review meta-analysis network meta-analysis

Select acute myocardial infarctionatrial fibrillationcardiac arrestheart failurepost myocardial infarction all type of heart failureAll type of patientmaintaining sinus rhythm after cardioversionout hospital patientsuncoded clinical condition ***rate control       amiodaroneamiodarone/dronedaroneantiarryhtmicClass IaClass IcClass II: Beta-blockersClass IIIdronedaronemagnesiumomega-3 polyunsaturated fatty acidsOthers class Iprophylactic lidocainerate control amiodaroneAzimilidedisopyramidedofetilidedronedaroneflecainidemagnesiummetoprololmoricizinepropafenonequinidinesotalol vs placebo or controlvs amiodaronevs Class Ivs Class Iavs Class Icvs Class IIvs Class IIIvs digoxinvs lidocainevs rate control      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (117)Atrial fibrillation recurrence (67)Pro-arrhythmia (61)Adverse events leading to treatment discontinuation (59)II-III atrio ventricular block (15)fatal ventricular fibrillation (14)non fatal VF (14)Heart failure (12)Cardiogenic shock (12)Ventricular fibrillation (11)severe arrhythmia (10)Bradycardia (8)Sudden death (7)death or hospitalization for cardiac causes (5)Hypotension (5)Arrhythmic/sudden death (5)Cardiac arrhythmic death (3)stroke (fatal and non fatal) (3)cardiovascular events (3)hospitalisation for heart failure (3)Cardiovascular death (2)survival to hospital admission (2)myocardial infarction (fatal and non fatal) (2)Death from any cause or hospitalization for any reason (1)Deep vein thrombosis (1)hospitalization for AF (1)Vascular noncardiac death (1)Cardiac nonarrhythmic death (1)Death before hospital admission (1)non cardiovascular death (1)combined endpoint (1)Major bleeding (1)stroke or TIA (1)Peripheral embolism (1)death by cardiac arrhythmia (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	Atrial fibrillation recurrence
acute myocardial infarction
dofetilide
DIAMOND MI, 1997	dofetilide	placebo			Low risk of bias	-
magnesium
ISIS-4, 1995	magnesium	control				suggesting
Wu, 1992	magnesium	control			Low risk of bias	suggesting
Zhu, 2002	magnesium	control				suggesting
Abraham, 1987	magnesium	placebo			Low risk of bias	negative
MAGIC, 2000      NCT	magnesium	placebo			Low risk of bias	negative
Bhargava, 1995	magnesium	placebo			Low risk of bias	suggesting
Ceremuzynski, 1989	magnesium	placebo				suggesting
Chen, 1991	magnesium	placebo				suggesting
Feldstedt, 1991	magnesium	placebo			Low risk of bias	negative
Gyamlani, 2000	magnesium	placebo			Low risk of bias	suggesting
Ising, 1990	magnesium	placebo				-
Morton, 1984	magnesium	placebo			Low risk of bias	negative
Nakashima, 2004	magnesium	placebo			Low risk of bias	negative
Parikka, 1990	magnesium	placebo			Low risk of bias	negative
Raghu, 1999	magnesium	placebo			Low risk of bias	suggesting
Rasmussen, 1986	magnesium	placebo			Low risk of bias	negative
Santoro, 2000	magnesium	placebo			Low risk of bias	negative
Shechter, 1990	magnesium	placebo			Low risk of bias	suggesting
Shechter, 1991	magnesium	placebo			Low risk of bias	negative
Shechter, 1995	magnesium	placebo			Low risk of bias	suggesting
Singh, 1990	magnesium	placebo			Low risk of bias	suggesting
Smith, 1986	magnesium	placebo			Low risk of bias	negative
Thogersen, 1995	magnesium	placebo			Low risk of bias	negative
Urek, 1996	magnesium	placebo			Low risk of bias	negative
Woods, 1992	magnesium	placebo			Low risk of bias	suggesting
moricizine
CAST II (early treatment), 1992	moricizine	placebo			Low risk of bias	-
atrial fibrillation
amiodarone
Channer, 2004	amiodarone	placebo			Low risk of bias	suggesting
GEFACA, 2001	amiodarone	placebo			Low risk of bias	suggesting
Kochiadakis (amiodarone vs placebo), 2000	amiodarone	placebo				suggesting
SAFE-T (amiodarone vs placebo), 2005	amiodarone	placebo			Low risk of bias	suggesting
AFFIRM Substudy (amiodarone vs class I drugs), 2003	amiodarone	class I drugs			Risk of bias	suggesting
AFFIRM Substudy (sotalol vs class I drugs), 2003	amiodarone	class I drugs				-
Villani, 1992	amiodarone	disopyramide				suggesting
Kochiadakis a, 2004	amiodarone	propafenone				negative
Vitolo, 1981	amiodarone	quinidine				suggesting
AFFIRM Substudy (amiodarone vs sotalol), 2003	amiodarone	sotalol				suggesting
Kochiadakis (amiodarone vs sotalol), 2000	amiodarone	sotalol				-
SAFE-T (amiodarone vs sotalol), 2005	amiodarone	sotalol			Low risk of bias	-
Azimilide
ASAP, 2003	Azimilide	placebo			Low risk of bias	negative
disopyramide
Karlson, 1998	disopyramide	placebo				negative
Lloyd (Disopyramide vs placebo), 1984	disopyramide	placebo			Low risk of bias	negative
PRODIS, 1996	disopyramide	propafenone			Low risk of bias	negative
Lloyd (Disopyramide vs quinidine), 1984	disopyramide	quinidine			Low risk of bias	-
dofetilide
DIAMOND, 2001	dofetilide	placebo			Low risk of bias	suggesting
SAFIRE-D, 2000	dofetilide	placebo			Low risk of bias	suggesting
dronedarone
EURIDIS, 2007      NCT	dronedarone	placebo			Low risk of bias	suggesting
ADONIS, 2007    NCT	dronedarone	placebo			Low risk of bias	suggesting
DAFNE, 2003	dronedarone	placebo			Low risk of bias	suggesting
EURIDIS ADONIS (pooled analysis), 2009	dronedarone	placebo			Low risk of bias	negative
ATHENA, 2009      NCT	dronedarone	placebo			Low risk of bias	suggesting
PALLAS, 2011        NCT	dronedarone	placebo			Low risk of bias	negative
ERATO, 2008	dronedarone	placebo			Low risk of bias	negative
DIONISOS, 2007      NCT	dronedarone	amiodarone			Low risk of bias	suggesting
flecainide
Van Gelder, 1989	flecainide	no treatment				negative
Carunchio (flecainide vs placebo), 1995	flecainide	placebo				suggesting
Steinbeck (flecainide vs digoxin), 1988	flecainide	digoxin				suggesting
Aliot, 1996	flecainide	propafenone				suggesting
Naccarelli, 1996	flecainide	quinidine			Low risk of bias	negative
metoprolol
Kuhlkamp, 2000	metoprolol	placebo				negative
propafenone
Bellandi (propafenone vs placebo), 2001	propafenone	placebo			Low risk of bias	suggesting
Dogan, 2004	propafenone	placebo				suggesting
Kochiadakis b (propafenone vs placebo), 2004	propafenone	placebo				suggesting
RAFT, 2003	propafenone	placebo			Low risk of bias	suggesting
Stroobandt, 1997	propafenone	placebo			Low risk of bias	negative
FAPIS, 1996	propafenone	flecainide				negative
Richiardi, 1992	propafenone	quinidine				negative
Reimold, 1993	propafenone	sotalol				negative
quinidine
Hillestad, 1971	quinidine	no treatment				negative
Sodermark, 1975	quinidine	no treatment				suggesting
Lloyd (quinidine vs placebo), 1984	quinidine	placebo			Low risk of bias	negative
PAFAC (quinidine vs placebo), 2004	quinidine	placebo			Low risk of bias	suggesting
SOPAT (quinidine vs placebo), 2004	quinidine	placebo			Low risk of bias	suggesting
Byrne Quinn, 1979	quinidine	placebo			Low risk of bias	suggesting
Steinbeck (quinidine vs digoxin), 1988	quinidine	digoxin				negative
Lloyd (quinidine vs disopyramide), 1984	quinidine	disopyramide			Low risk of bias	-
Steinbeck (quinidine vs flecainide), 1988	quinidine	flecainide				-
Hohnloser, 1995	quinidine	sotalol				negative
Juul-Moller, 1990	quinidine	sotalol				negative
Kalusche, 1994	quinidine	sotalol				negative
SOCESP, 1999	quinidine	sotalol				negative
PAFAC (quinidine vs sotalol), 2004	quinidine	sotalol			Low risk of bias	-
SOPAT (quinidine vs sotalol), 2004	quinidine	sotalol			Low risk of bias	-
sotalol
Benditt, 1999	sotalol	placebo			Low risk of bias	negative
Singh, 1991	sotalol	placebo			Low risk of bias	suggesting
Bellandi (sotalol vs placebo), 2001	sotalol	placebo			Low risk of bias	suggesting
Carunchio (sotalol vs placebo), 1995	sotalol	placebo				suggesting
Kochiadakis (sotalol vs placebo), 2000	sotalol	placebo				-
Kochiadakis b (sotalol vs placebo), 2004	sotalol	placebo				suggesting
PAFAC (sotalol vs placebo), 2004	sotalol	placebo			Low risk of bias	suggesting
SAFE-T (sotalol vs placebo), 2005	sotalol	placebo			Low risk of bias	suggesting
SOPAT (sotalol vs placebo), 2004	sotalol	placebo			Low risk of bias	negative
Plewan, 2001	sotalol	bisoprolol				negative
Carunchio (sotalol vs flecianide), 1995	sotalol	flecainide				-
Kochiadakis b (sotalol vs propafenome), 2004	sotalol	propafenone				-
cardiac arrest
amiodarone
ARREST, 1999	amiodarone	placebo			Low risk of bias	suggesting
ALIVE, 2002	amiodarone	lidocaine			Low risk of bias	suggesting
heart failure
amiodarone
EPAMSA, 1985	amiodarone	no treatment				suggesting
GESICA, 1994	amiodarone	no treatment				suggesting
Hamer, 1989	amiodarone	placebo			Low risk of bias	suggesting
Nicklas, 1991	amiodarone	placebo			Low risk of bias	negative
STATCHF, 1995	amiodarone	placebo			Low risk of bias	negative
AMIOVIRT, 2003	amiodarone	ICD				negative
dronedarone
ANDROMEDA, 2008      NCT	dronedarone	placebo			Low risk of bias	negative
post myocardial infarction
amiodarone
BASIS, 1990	early amiodarone	control				suggesting
Navarro-Lopez, 1993	early amiodarone	control				negative
CAMIAT , 1991	early amiodarone	placebo			Low risk of bias	negative
Ceremuzynski, 1992	early amiodarone	placebo			Low risk of bias	negative
Hockings, 1987	early amiodarone	placebo			Low risk of bias	negative
Azimilide
ALIVE, 2004	azimilide	placebo			Low risk of bias	-
dofetilide
DIAMOND MI, 1997	dofetilide	placebo			Low risk of bias	-
moricizine
CAST II (early treatment), 1992	moricizine	placebo			Low risk of bias	-
CAST II (late treatment), 1992	moricizine	placebo			Low risk of bias	-